Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742027 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
A Phase 2 study of Classical Hodgkin's Lymphoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 20
- Study locations
NCT00742027: Completed Phase 2 study of Classical Hodgkin's Lymphoma, sponsored by Novartis Pharmaceuticals.
NCT00742027 is a Phase 2 study of Classical Hodgkin's Lymphoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 129 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00742027, a Phase 2 study of Classical Hodgkin's Lymphoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was assessed. Other markers that may correlate with efficacy or safety were explored.
Primary Outcome
ORR was number of participants with best overall disease response of complete response(CR)/partial response(PR).Best overall disease response was best disease response recorded from start of treatment until disease progression/recurrence.CR=complete normalization of all index nodal,extranodal lesions,complete disappearance of all extranodal lesions.PR=50% decrease in SPD for up to 6 identified dominant lesions (splenic,hepatic nodules) from baseline.Stable=neither sufficient shrinkage to qualify
Conditions Studied
Interventions
- DRUG Panobinostat
Study Locations (20)
Texas
- University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3) - Houston
- The Methodist Hospital Cell & Gene Therapy Clinic - Houston
- Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5) - San Antonio
Other
- Novartis Investigative Site - Brussels
- Novartis Investigative Site - Charleroi
- Novartis Investigative Site - Leuven
Georgia
- Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) - Atlanta
- Georgia Regents University Cancer Clinical Research Unit - Augusta
California
- City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(2) - Duarte
Illinois
- Rush University Medical Center Divisionof Hem/Onc Research(2) - Chicago
Maryland
- VA Maryland Health Care Dept.of GreenbaumCancerCent(5) - Baltimore
Massachusetts
- Dana Farber Cancer Institute Hematology / Oncology - Boston
Michigan
- Karmanos Cancer Institute Div.of Hematology/Oncology - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2008-09-16 |
| Est. Completion | 2013-08-12 |
| Phase | Phase 2 |
What the finished NCT00742027 record still lists
NCT00742027 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Classical Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Panobinostat is the first listed.
NCT00742027 names 20 study sites across 15 states, led by Texas, Other, Georgia.
Frequently Asked Questions
What is clinical trial NCT00742027 about?
NCT00742027 is a clinical study titled "Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma". This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was assessed. Other markers that may correla...
What is the current status of trial NCT00742027?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2008-09-16. Estimated completion is 2013-08-12.
What conditions does trial NCT00742027 study?
This clinical trial studies the following conditions: Classical Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00742027?
The interventions under investigation include: Panobinostat (DRUG).
Who is sponsoring clinical trial NCT00742027?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00742027 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00742027's enrollment target sits among peer trials
129 553rd of 2000 higher than 1,448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI